IGI Logo

Glenmark Pharmaceuticals is currently trading at Rs. 371.40, up by 0.10 points or 0.03% from its previous closing of Rs. 371.30 on the BSE.

The scrip opened at Rs. 372.00 and has touched a high and low of Rs. 374.90 and Rs. 371.10 respectively. So far 27760 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 389.95 and Rs. 361.70 respectively. The current market cap of the company is Rs. 10474.08 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.73% and 18.63% respectively.

Glenmark Pharmaceuticals’ subsidiary -- Hikma Pharmaceuticals PLC (Hikma Group) has launched Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. Ryaltris is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US. Ryaltris is the only fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.